Saha, N., Lee, S. G., Brockmann, E.-C., de la Cruz, M. J., Goldgur, Y., Mendoza, R. P., Stanchina, E. de, Love, T. M., Marvald, J., Xu, Y., Xu, K., Himanen, J. P., Lamminmäki, U., Veach, D., & Nikolov, D. B. (2024). Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells. Biomedicine & Pharmacotherapy, 180, 117605. https://doi.org/10.1016/j.biopha.2024.117605

Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., … Armstrong, A. J. (2024). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.09.005

Felip, E., Shu, C. A., Aguilar, A., Tang, K.-J., García Campelo, M. R., Lee, K.-Y., Delmonte, A., Sabari, J., Girard, N., Mansfield, A. S., Park, K., Zhou, C., Xia, K., Bhattacharya, A., Wade, M., Baig, M., Agrawal, T., Mahadevia, P., Knoblauch, R. E., & Sanborn, R. E. (2024). 2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON. ESMO Open, 9, 102581. https://doi.org/10.1016/j.esmoop.2024.102581

Bupathi, M., Wang, J. S., Hu-Lieskovan, S., Piha-Paul, S. A., Chmielowski, B., Garmezy, B., Najjar, Y. G., Stein, M. N., Yao, L., Kanodia, J., Clynes, R., McGovern, P., & Thompson, B. (2023). 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0764

Baljevic, M., Moreau, P., Tuchman, S., Callander, N., Lentzsch, S., Van Domelen, D., Bentur, O., Monge, J., & Biran, N. (2023). P-232 Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clinical Lymphoma Myeloma and Leukemia, 23, S163. https://doi.org/10.1016/s2152-2650(23)01850-5

Bansode, A. H., Bhoopal, B., Gollapelli, K. K., Damuka, N., Krizan, I., Miller, M., Craft, S., Mintz, A., & Solingapuram Sai, K. K. (2023). Binding Parameters of [11C]MPC-6827, a Microtubule-Imaging PET Radiopharmaceutical in Rodents. Pharmaceuticals, 16(4), 495. https://doi.org/10.3390/ph16040495

Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668

Hamid, O., Sato, T., Davar, D., Callahan, M. K., Thistlethwaite, F., Aljumaily, R., Johnson, M. L., Arkenau, H.-T., Ileana Dumbrava, E. E., Izar, B., Chen, H. A., Marshall, S., Yuan, Y., Deo, M., Stanhope, S., Collins, L., Mundy, R., Abdullah, S. E., & Lopez, J. S. (2022). 728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology, 33, S875. https://doi.org/10.1016/j.annonc.2022.07.854

Lim, E., Reeves, J., Gandhi, S., Spigel, D. R., Arrowsmith, E., George, D. J., Karlix, J., Pouliot, G., Hattersley, M., Gangl, E., James, G., Thompson, J., Russell, D., Patel, B., Kumar, R., & Falchook, G. S. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology, 33, S1182–S1183. https://doi.org/10.1016/j.annonc.2022.07.1882

Rosenblat, T. L., McDevitt, M. R., Carrasquillo, J. A., Pandit-Taskar, N., Frattini, M. G., Maslak, P. G., Park, J. H., Douer, D., Cicic, D., Larson, S. M., Scheinberg, D. A., & Jurcic, J. G. (2022). Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 28(10), 2030–2037. https://doi.org/10.1158/1078-0432.ccr-21-3712

Sharma, M. R., Carvajal, R. D., Hanna, G. J., Kang, Y. K., Lee, J., Lee, K. W., Li, B. T., Moore, K. N., Pegram, M., Rasco, D., Spira, A., Wang, D., Weinberg, B. A., Alonso, M., Fang, L., Husain, A., Kowanetz, M., Perez, E. A., & Dumbrava, E. I. (2021). 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Annals of Oncology, 32, S1453–S1454. https://doi.org/10.1016/j.annonc.2021.10.183